Comparison of intra-articular injection of dexmedetomidine and triamcinolone in improving knee pain and function in patients with primary knee osteoarthritis.

Comparison of efficacy and safety of intra-articular injection of dexmedetomidine and triamcinolone in improving knee pain and function in patients with primary knee osteoarthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130518013364N11

Enrollment

Registered

2023-09-27

Start date

2023-10-02

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of knee. Bilateral primary osteoarthritis of knee

Interventions

Intervention 1: Intervention group: Injection of dexmedetomidine 1 microgram per kilogram + 2 ml lidocaine 2%, which is performed under ultrasound guidance with a 27-gauge needle inside the knee joint

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 40 years Presence of knee pain for more than 3 months Radiological findings confirming knee osteoarthritis based on American College of Rheumatology (ACR) criteria

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Patients with a history of knee surgery Patients with lower limb deformity and contracture Patients with lower limb neuromuscular disease Patients with acute lumbar pathology Injection of steroid drugs during the last two months History of inflammatory rheumatoid arthritis History of recent infection in the knee Diabetes Pregnancy Breastfeeding BMI> 35 Candidate patients for knee surgery The presence of knee deviation (Varus or valgus more than five degrees) which was confirmed by three joint view The presence of radicular pain Taking anticoagulants Arthritis after trauma History of intra-articular injection of the knee during the last 12 months Allergy to any of the drugs used Chronic systemic disease Psychiatric illness Severe osteoarthritis with grade more than III Hepatitis Cytomegalovirus infection Having syphilis Having osteomyelitis Drug and alcohol abuse Having AIDS

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: At the beginning of the study (before the start of the intervention) and one and three months after. Method of measurement: Visual analog scale.;The total score of the KOOS questionnaire. Timepoint: At the beginning of the study (before the start of the intervention) and one and three months after. Method of measurement: Based on asking the patient and scoring each of the items.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Taheri

Shahid Beheshti University of Medical Sciences

m.taheri@sbmu.ac.ir+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026